- Home
- KROS vs GNE Comparison
KROS vs GNE Comparison
Compare KROS & GNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- GNE
- Stock Information
- Founded
- KROS 2015
- GNE 2011
- Country
- KROS United States
- GNE United States
- Employees
- KROS N/A
- GNE N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- GNE Power Generation
- Sector
- KROS Health Care
- GNE Utilities
- Exchange
- KROS Nasdaq
- GNE Nasdaq
- Market Cap
- KROS 461.6M
- GNE 402.8M
- IPO Year
- KROS 2020
- GNE N/A
- Fundamental
- Price
- KROS $11.47
- GNE $14.06
- Analyst Decision
- KROS Buy
- GNE
- Analyst Count
- KROS 11
- GNE 0
- Target Price
- KROS $30.00
- GNE N/A
- AVG Volume (30 Days)
- KROS 953.9K
- GNE 84.7K
- Earning Date
- KROS 05-07-2025
- GNE 03-10-2025
- Dividend Yield
- KROS N/A
- GNE 2.10%
- EPS Growth
- KROS N/A
- GNE N/A
- EPS
- KROS N/A
- GNE 0.46
- Revenue
- KROS $3,550,000.00
- GNE $425,202,000.00
- Revenue This Year
- KROS $16.65
- GNE N/A
- Revenue Next Year
- KROS $107.46
- GNE N/A
- P/E Ratio
- KROS N/A
- GNE $25.00
- Revenue Growth
- KROS 2250.99
- GNE N/A
- 52 Week Low
- KROS $9.78
- GNE $13.05
- 52 Week High
- KROS $72.37
- GNE $17.93
- Technical
- Relative Strength Index (RSI)
- KROS 44.86
- GNE 43.39
- Support Level
- KROS $10.62
- GNE $13.76
- Resistance Level
- KROS $12.28
- GNE $14.93
- Average True Range (ATR)
- KROS 0.60
- GNE 0.53
- MACD
- KROS 0.34
- GNE -0.05
- Stochastic Oscillator
- KROS 51.20
- GNE 49.80
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About GNE Genie Energy Ltd. Class B Stock
Genie Energy Ltd, through its subsidiaries, operates as a retail energy provider. It serves two reportable business segments: Genie retail energy, or GRE, and Genie renewables. The Genie retail energy segment resells energy to residential and commercial consumers in the Eastern and Midwestern United States through its portfolio of various retail energy providers. The Genie renewables segment holds controlling interests in various companies engaged in the manufacturing of solar panels, solar installation design, and solar energy project management. It generates the majority of its revenue from the Genie retail energy segment.